Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

This article is part of the supplement: Proceedings of the Second Workshop of the Regional Study Group on HCV in the Calabria Region (Southern Italy). The virus-host-therapy pathway in HCV disease management: from bench to bedside in the era of Directly Acting Antivirals

Open Access Review

Top topics in HCV research arena

Massimo Puoti*, Roberto Rossotti, Giovanna Travi, Maurizio Orso and Maria Cristina Moioli

Author Affiliations

Infectious Diseases Unit AO Ospedale Niguarda Ca’ Granda, 20162 Milano, Italy

For all author emails, please log on.

BMC Infectious Diseases 2012, 12(Suppl 2):S7  doi:10.1186/1471-2334-12-S2-S7

Published: 12 November 2012


A significant improvement in the rate of eradication of Hepatitis C Virus Genotype 1 has been achieved with the addition of Boceprevir and Telaprevir to pegylated interferon and ribavirin. These two drugs are the heralds of a new wave of antivirals that will improve the efficacy of pegylated interferon or even will substitute this drug in interferon free combinations. The results of phase II studies in patients naïve to treatment seem to be very promising strongly supporting the possibility of a large success for a first line all oral antiviral combination in interferon naïve. However, data observed in interferon experienced patients are less exciting and probably more complex treatment regimens will be needed to treat this patients’ population.